Adicet Bio stock sinks on proposed public offering
https://seekingalpha.com/news/4057105-adicet-bio-stock-sinks-on-proposed-public-offering?source=feed_sector_healthcare
Jan 22, 2024 - Adicet Bio starts underwritten public offering, causing its stock to plummet by 15.3%.
0
Adicet Bio announces pricing of public offering
https://seekingalpha.com/news/4057425-adicet-bio-announces-pricing-of-public-offering?source=feed_sector_healthcare
Jan 23, 2024 - Adicet Bio announces the pricing of its public offering, with expected gross proceeds of $85.2M, to close on January 25, 2024.
0
Tourmaline Bio looks to raise cash through a public offering
https://seekingalpha.com/news/4058138-tourmaline-bio-looks-to-raise-cash-through-a-public-offering?source=feed_sector_healthcare
Jan 24, 2024 - Tourmaline Bio announces proposed public offering of common stock. Underwriters may purchase additional shares.
0
2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up
https://www.zacks.com/stock/news/2218877/2seventy-bio-tsvt-divests-r-d-assets-to-regeneron-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2218877
Jan 31, 2024 - 2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.
0
SPAC Semper Paratus shareholders okay merger with Tevogen Bio
https://seekingalpha.com/news/4061494-spac-semper-paratus-shareholders-okay-merger-with-tevogen-bio?source=feed_sector_healthcare
Feb 01, 2024 - SPAC Semper Paratus Acquisition Corp. (LGST) shareholders have approved a merger deal with immunotherapy developer Tevogen Bio (TVGN). Read more here.
0
Intelligent Bio Solutions Expects Higher Q2 Revenue, Stock Up In Pre-Market
https://www.rttnews.com/story.aspx?Id=3421577
Feb 02, 2024 - Medical technology company Intelligent Bio Solutions Inc. (INBS), Friday announced that it expects higher revenue for its second quarter. The preliminary outlook is mainly due to increased demand for its drug screening solution, and expansion into new global markets.
0
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
https://www.zacks.com/stock/news/2224777/is-adicet-bio-acet-outperforming-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2224777
Feb 12, 2024 - Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
0
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?
https://www.zacks.com/stock/news/2233203/is-adicet-bio-acet-stock-outpacing-its-medical-peers-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2233203
Feb 28, 2024 - Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
0
Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates
https://www.zacks.com/stock/news/2236964/generation-bio-co-gbio-reports-q4-loss-lags-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2236964
Mar 06, 2024 - Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -29.27% and 5.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Should You Buy Gossamer Bio (GOSS) After Golden Cross?
https://www.zacks.com/stock/news/2237343/should-you-buy-gossamer-bio-goss-after-golden-cross?cid=CS-ZC-FT-tale_of_the_tape|golden_crossover-2237343
Mar 07, 2024 - Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
0
Page 1>